Exploring Recent Guideline Updates Relating to the Management of Hyperlipidemia
Viet Le, DMSc, MPAS, PA-C, FACC, FAHA, discusses how various nonstatin LDL-lowering therapies including ezetimibe, bempedoic acid and PCSK9 inhibitors can be used in combination to achieve aggressive cholesterol targets for cardiovascular risk reduction, particularly in patients with statin intolerance or those requiring intensive secondary prevention.
EP. 1: The Role of LDL-Lowering Therapies and Defining Statin Intolerance
September 30th 2025An expert discusses how primary and secondary prevention differ in atherosclerotic cardiovascular disease, with secondary prevention targeting patients who have already had events such as heart attacks or strokes and primary prevention addressing high-risk patients with multiple risk factors. He explains that statin intolerance can be complete (due to severe complications such as rhabdomyolysis) or partial (ranging from mild to severe muscle aches), while statin resistance occurs when patients tolerate the medication but don’t achieve expected LDL cholesterol reductions.
Watch
